Medtronic has terminated its $738 million deal to buy wearable insulin patch maker EOFlow Co.
The medical-technology company disclosed the cancellation Wednesday in a brief filing with the U.S. Securities and Exchange Commission that offered few details.
"Medtronic has exercised its rights to terminate its agreement to acquire EOFlow as a result of multiple breaches on their part," the company said in a statement. Medtronic did not specify the alleged breaches.
Medtronic announced plans to buy South Korea-based EOFlow in May. The proposed deal was seen as a significant step as the company rebuilds its diabetes business.
When the deal was unveiled, Medtronic expected it would close before the end of the year.
EOFlow makes a tubeless, wearable and fully disposable insulin-delivery device. Medtronic had planned to quickly integrate EOFlow into its global diabetes business.
EOFlow, founded in 2011, has been embroiled in legal issues. Massachusetts-based Insulet Corp., which makes a patch insulin pump, sued EOFlow in the summer, charging that its technology was based on stolen trade secrets. Medtronic is not a party to the litigation but has been monitoring the case.
The company's SEC filing noted the termination "does not impact Medtronic's fiscal year 2024 adjusted earnings per share guidance range."